Ruxolitinib Sandoz 5 mg

Ruxolitinib Sandoz 5 mg is a medicine authorised by Swissmedic under authorisation number 70733. The authorisation holder is Sandoz Pharmaceuticals AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 04 May 2026 and the authorisation is limited until 03 May 2031. ATC code L01EJ01 places the medicine in the group Antineoplastic agents.

  • Dispensing category A
  • Authorisation number 70733
  • ATC L01EJ01
  • Synthetic medicines
Authorisation data
Authorisation number70733
NameRuxolitinib Sandoz 5 mg
Full nameRuxolitinib Sandoz 5 mg, Tabletten
Authorisation holderSandoz Pharmaceuticals AG
Medicinal product codeSynthetic medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeL01EJ01
First authorisation04 May 2026
Authorisation validity03 May 2031
Strengths
No.NameDispensing categoryAuthorisation date
1Ruxolitinib Sandoz 5 mg, TablettenA04 May 2026
2Ruxolitinib Sandoz 10 mg, TablettenA04 May 2026
3Ruxolitinib Sandoz 15 mg, TablettenA04 May 2026
4Ruxolitinib Sandoz 20 mg, TablettenA04 May 2026

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
156Tablette(n)L01EJ0107.16.1.A
2168Tablette(n)L01EJ0107.16.1.A
356Tablette(n)L01EJ0107.16.1.A
4168Tablette(n)L01EJ0107.16.1.A
556Tablette(n)L01EJ0107.16.1.A
6168Tablette(n)L01EJ0107.16.1.A
756Tablette(n)L01EJ0107.16.1.A
8168Tablette(n)L01EJ0107.16.1.A

Scroll the table sideways

Medicines in the same ATC group

Other medicines from this authorisation holder

Frequently asked questions

Is Ruxolitinib Sandoz 5 mg authorised in Switzerland?

Yes. Ruxolitinib Sandoz 5 mg is authorised by Swissmedic under authorisation number 70733, data as of 01 September 2026. The authorisation is limited until 03 May 2031.

Which dispensing category does Ruxolitinib Sandoz 5 mg have?

Ruxolitinib Sandoz 5 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Ruxolitinib Sandoz 5 mg?

The authorisation holder is Sandoz Pharmaceuticals AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com